Breast milk market is booming online – it's unregulated, might make your baby sick, but entirely legal
Icahn Enterprises L.P. Announces Hiring of Dr. Richard C. Mulligan
NEW YORK, March 01, 2017 -- Icahn Enterprises L.P. (NASDAQ:IEP) today announced that Icahn Capital LP, its wholly owned subsidiary, has hired Dr. Richard C. Mulligan as a Portfolio Manager. Dr. Mulligan will be focused on biotechnology investments for Icahn Partners LP and Icahn Partners Master Fund LP, the private investment funds comprising Icahn Enterprises’ Investment segment.
"We are very pleased to have Richard join Icahn Capital given the depth and level of experience he brings as we look to enhance our focus on the biotechnology sector," said Carl C. Icahn, Chairman of Icahn Enterprises.
Richard C. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, and Visiting Scientist at the Koch Institute for Integrative Cancer Research at MIT. Previously, Professor Mulligan was the Mallinckrodt Professor of Genetics at Harvard Medical School, and Director of the Harvard Gene Therapy Initiative, an integrated effort amongst basic science and clinical investigators at Harvard University and its Affiliated Hospitals directed towards the pre-clinical and clinical evaluation of novel gene-based therapies for inherited and acquired diseases. Professor Mulligan received his B.S. degree from Massachusetts Institute of Technology (MIT), and his Ph.D. from the Department of Biochemistry at Stanford University School of Medicine, where he studied under Nobel Laureate Paul Berg. After receiving postdoctoral training at the Center for Cancer Research at MIT with Nobel Laureates David Baltimore and Phillip Sharp, Professor Mulligan joined the MIT faculty and subsequently was appointed Professor of Molecular Biology and Member of the Whitehead Institute for Biomedical Research before moving to Harvard and Children’s Hospital in 1996. His honors include the MacArthur Foundation ‘Genius’ Prize, the Rhodes Memorial Award of the American Association for Cancer Research, the ASMB-Amgen Award, and the Nagai Foundation International Prize.
Professor Mulligan is an internationally recognized pioneer in the development of new technologies for transferring genes into mammalian cells. A major interest in Professor Mulligan’s laboratory has been the development of genetically engineered animal viruses as gene transfer ‘vectors’. Scientists use the specialized tools created in his laboratory to unravel basic questions about human development and to devise new clinical ‘gene therapies’ for the treatment of both inherited diseases and acquired diseases.
Professor Mulligan has been previously associated with a number of public biotechnology and pharmaceutical companies, either as a consultant or as a member of the company’s Board of Directors (BOD). These companies include: Dupont (consultant), Genetics Institute (consultant), Amgen (consultant), Somatix Therapy Corporation (founder, scientific advisory board (SAB), chief scientific officer (CSO), and member, BOD), Cell Genesys (SAB), Imclone (SAB, member, BOD, and member of Executive Committee of the Board), Cellectis (member, BOD, then private), Enzon (member, BOD), and, currently, Biogen (member, BOD). He has also served on the US National Institutes of Health Recombinant DNA Advisory Committee (RAC), which provides guidance to the NIH regarding experiments involving recombinant DNA, and on the FDA Biological Response Modifiers Advisory Committee (BRMAC), which advises the FDA on matters related to cell and gene therapies, including stem cell-based technologies.
From 2013-2016, Professor Mulligan was Founding Partner and Senior Managing Director of Sarissa Capital Management LP.
Icahn Enterprises L.P. (NASDAQ:IEP), a master limited partnership, is a diversified holding company engaged in ten primary business segments: Investment, Automotive, Energy, Railcar, Gaming, Metals, Mining, Food Packaging, Real Estate and Home Fashion.
Investor Contacts: SungHwan Cho, Chief Financial Officer Peter Reck, Chief Accounting Officer (212) 702-4300
Tesla Cybertruck update: Is Elon Musk's futuristic pickup truck joining the 'Cyberpunk 2077' vehicle lineup?